Ocugen’s model fair value holds at US$11.43 per share, with no change to the underlying price target despite fresh clinical and financing updates. That stability reflects a cautious analyst stance that reins in more aggressive valuation assumptions while still recognizing the early stage profile of Ocugen’s pipeline. As you read on, you will see how this updated narrative, and the data behind it, can help you track Ocugen’s evolving story. Analyst Price Targets don't always capture the full...
News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
534last 24h
2502last 7d
489● bullish (7d)
260● bearish (7d)
200publishers
Simply Wall St.42d agoneutral
Ocugen (OCGN) Stock Draws Fresh Price Target Split After Cautious Analyst ViewZacks90d agobullish
Ocugen (OCGN) Upgraded to Buy: Here's WhyOcugen (OCGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).